Canaccord Genuity and Stifel will be the joint bookrunning managers
By Devika Patel
Knoxville, Tenn., May 30 - LeMaitre Vascular, Inc. priced a $10.01 million public offering of stock with a $1.5 million greenshoe, according to a prospectus supplement and 8-K filed Friday with the Securities and Exchange Commission. The deal was announced Thursday.
The company will sell 1.43 million common shares at $7.00 apiece. The price per share is an 8.26% discount to the May 29 closing share price of $7.63.
Canaccord Genuity and Stifel are the joint bookrunners.
Settlement is expected June 4.
Proceeds will be used for general corporate purposes, including product development, working capital and capital expenditures.
The Burlington, Mass., company develops medical devices and implants for the treatment of peripheral vascular disease.
| Issuer: | LeMaitre Vascular, Inc.
|
| Issue: | Common shares
|
| Amount: | $10.01 million
|
| Greenshoe: | $1,501,500
|
| Shares: | 1.43 million
|
| Price: | $7.00
|
| Warrants: | No
|
| Bookrunners: | Canaccord Genuity and Stifel
|
| Co-managers: | Roth Capital Partners, Barrington Research Associates, Benchmark Co. and Brean Capital
|
| Announcement date: | May 29
|
| Pricing date: | May 30
|
| Settlement date: | June 4
|
| Stock symbol: | Nasdaq: LMAT
|
| Stock price: | $7.63 at close May 29
|
| Market capitalization: | $116.48 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
